机构：[1]Departments of Structural & Cellular Biology, Tulane University, New Orleans, LA, USA[2]Departments of Orthopaedic Surgery, Tulane University, New Orleans, LA, USA外科科室妇产科妇科昆明医科大学附属第一医院[3]Department of Gynecology, The First Affiliated Hospital of Kunming Medical University, Kunming, China外科科室妇产科妇科昆明医科大学附属第一医院[4]Department of Clinical Medicine, The Second Affiliated Hospital, Shaanxi University of Chinese Medicine, Xi’an, China[5]Department of Computer Science and Biostatistics Facility of RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA, USA[6]Department of Biochemistry and Cancer Biology, School of Medicine, Meharry Medical College, Nashville, TN, USA[7]Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane University, New Orleans, LA, USA[8]Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, LA, USA[9]Tulane Center for Aging, Tulane University, New Orleans, LA, USA[10]Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA
Interleukin-17 (IL-17) has been demonstrated to promote development of a variety of cancers including prostate cancer in genetically modified mouse models. IL-17 is the main product secreted by T helper 17 (Th17) cells. A recent study has shown that Th17 cells and related genes are upregulated in human prostate cancers. However, there is no direct experimental evidence to demonstrate Th17's role in prostate cancer. In the present study, we co-implanted mouse prostate cancer MPC3-luc cells with Th17-polarized mouse splenocytes in the prostate of immunocompetent C57BL/6J male mice. We found that Th17-polarized splenocytes promoted orthotopic allograft prostate tumor growth compared to the control splenocytes. The numbers of IL-17-positive lymphocytes and macrophages were higher in the prostate tumors grown from co-implantation of MPC3-luc cells and Th17-polarized splenocytes, compared to the prostate tumors grown from co-implantation of MPC3-luc cells and control splenocytes. Our findings provide the first direct experimental evidence that Th17 cells may promote prostate cancer growth.
基金：
Dr. Zongbing
You was partially supported by National
Institutes of Health (R01CA174714), Department
of Defense (W81XWH-15-1-0444), the Transformative
Experiment Fund of Tulane Cancer
Center (TCC), Louisiana Cancer Research
Consortium (LCRC) Fund, the Carol Lavin Bernick
Faculty Grant that was donated by the Carol
Lavin Bernick Family Foundation to Tulane University,
and Merit Review Award (I01BX004158)
from the Department of Veterans Affairs, Veterans
Health Administration, Office of Research
and Development, Biomedical Laboratory
Research & Development Service. Dr. Zongbing
You is a Research Physiologist employed by
the Research Service, Southeast Louisiana
Veterans Health Care System, New Orleans,
LA-629. Dr. Kun Zhang was partially supported
by Research Centers in Minority Institutions
(RCMI) funded by National Institutes of Health
(2U54MD007595). The content of this article is
solely the responsibility of the authors and
does not necessarily represent the official views
or policies of the National Institutes of
Health, Department of Defense, or Department
of Veterans Affairs or the United States government.
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]Departments of Structural & Cellular Biology, Tulane University, New Orleans, LA, USA[3]Department of Gynecology, The First Affiliated Hospital of Kunming Medical University, Kunming, China
通讯作者：
通讯机构：[1]Departments of Structural & Cellular Biology, Tulane University, New Orleans, LA, USA[2]Departments of Orthopaedic Surgery, Tulane University, New Orleans, LA, USA[7]Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane University, New Orleans, LA, USA[8]Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, LA, USA[9]Tulane Center for Aging, Tulane University, New Orleans, LA, USA[10]Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA[*1]Department of Structural & Cellular Biology, Tulane University School of Medicine, 1430 Tulane Avenue Mailbox 8649, New Orleans, Louisiana 70112, USA[*2]Southeast Louisiana Veterans Health Care System 2400 Canal St, New Orleans, LA 70119, USA.
推荐引用方式(GB/T 7714)：
Zhenling Duan,Haiyan D Miller,Xiaowei Fu,et al.Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer.[J].American journal of clinical and experimental urology.2019,7(4):249-261.
APA：
Zhenling Duan,Haiyan D Miller,Xiaowei Fu,Dongxia Ge,Ben Jin...&Zongbing You.(2019).Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer..American journal of clinical and experimental urology,7,(4)
MLA：
Zhenling Duan,et al."Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer.".American journal of clinical and experimental urology 7..4(2019):249-261
